Telix Pharmaceuticals Q2 Revenue Climbs Boosted By Precision Medicine Businessrttnews·Jul 21 at 12:45 AMTLX-0.40%
3 Australian Growth Stocks Trading Below Fair Value With Strong Insider BackingSimplywall·Jul 21 at 12:09 AMTLX-0.40%
Telix Pharmaceuticals reports Q2 results; updates FY2026 outlookbusinessinsider·Jul 20 at 11:30 PMTLX-0.40%
Bell Potter Sticks to Its Buy Rating for Telix Pharmaceuticals (TLPPF)Tip Ranks·Jul 20 at 07:35 PMTLX-0.40%
TLX: Q2 2026 revenue up 21% YoY to US $247M, with FY 2026 revenue expected to surpass US $1BQuartr·Jul 20 at 05:41 PMTLX-0.40%REGN+6.17%
Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer | TLX Stock NewsStockTitan·Jul 20 at 08:00 AMTLX-0.40%
Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress | TLX Stock NewsStockTitan·Jul 20 at 10:31 AMTLX-0.40%REGN+6.17%
